R M Carnahan

Summary

Affiliation: University of Oklahoma Health Sciences Center
Country: USA

Publications

  1. doi request reprint Consistency of antidepressant and chronic nonpsychiatric medication use in a high-risk clinical population
    Ryan M Carnahan
    The University of Oklahoma, Department of Pharmacy Clinical and Administrative Sciences, 4502 E 41st St, Suite 2H19, Tulsa, OK 74135 2512, USA
    Res Social Adm Pharm 4:367-74. 2008
  2. ncbi request reprint The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity
    Ryan M Carnahan
    University of Oklahoma College of Pharmacy, Department of Pharmacy, Tulsa, Oklahoma 74315 2512, USA
    J Clin Pharmacol 46:1481-6. 2006
  3. ncbi request reprint Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy
    R M Carnahan
    Department of Pharmacy Clinical and Administrative Sciences, The University of Oklahoma College of Pharmacy, Tulsa, OK 74135, USA
    Acta Psychiatr Scand 113:135-41. 2006
  4. ncbi request reprint Acute ethanol intoxication after consumption of hairspray
    Ryan M Carnahan
    Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Oklahoma, Tulsa, Oklahoma 74315 2512, USA
    Pharmacotherapy 25:1646-50. 2005
  5. ncbi request reprint Ziprasidone, a new atypical antipsychotic drug
    R M Carnahan
    Clinical and Administrative Pharmacy Division, College of Pharmacy, University of Iowa, Iowa City 52242-1112, USA
    Pharmacotherapy 21:717-30. 2001
  6. ncbi request reprint Rivastigmine-induced dystonia
    Clay J Pavlis
    Sanford School of Medicine, University of South Dakota USD, Sioux Falls 57110, USA
    Am J Health Syst Pharm 64:2468-70. 2007
  7. ncbi request reprint Severe hyperlipidemia associated with olanzapine and quetiapine use
    Ryan M Carnahan
    Am J Psychiatry 164:1614-5. 2007
  8. ncbi request reprint Clozapine-induced leukopenia successfully treated with lithium
    Eric C Kutscher
    College of Pharmacy, South Dakota State University, Sioux Falls, SD 57110, USA
    Am J Health Syst Pharm 64:2027-31. 2007
  9. ncbi request reprint Quetiapine for acute mania in bipolar disorder
    Nancy C Brahm
    Department of Pharmacy Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy UOCP, Tulsa, OK 74135 2512, USA
    Am J Health Syst Pharm 64:1045-53. 2007
  10. ncbi request reprint The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?
    Ryan M Carnahan
    Clinical and Administrative Pharmacy, College of Pharmacy, University of Iowa, Iowa City, USA
    J Am Geriatr Soc 52:2082-7. 2004

Collaborators

Detail Information

Publications15

  1. doi request reprint Consistency of antidepressant and chronic nonpsychiatric medication use in a high-risk clinical population
    Ryan M Carnahan
    The University of Oklahoma, Department of Pharmacy Clinical and Administrative Sciences, 4502 E 41st St, Suite 2H19, Tulsa, OK 74135 2512, USA
    Res Social Adm Pharm 4:367-74. 2008
    ..Although antidepressant persistence has been well described, little is known about consistency patterns...
  2. ncbi request reprint The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity
    Ryan M Carnahan
    University of Oklahoma College of Pharmacy, Department of Pharmacy, Tulsa, Oklahoma 74315 2512, USA
    J Clin Pharmacol 46:1481-6. 2006
    ..This study replicated findings on the association of the ADS with SAA. Future work will determine whether the ADS is clinically useful for preventing anticholinergic adverse effects...
  3. ncbi request reprint Increased risk of extrapyramidal side-effect treatment associated with atypical antipsychotic polytherapy
    R M Carnahan
    Department of Pharmacy Clinical and Administrative Sciences, The University of Oklahoma College of Pharmacy, Tulsa, OK 74135, USA
    Acta Psychiatr Scand 113:135-41. 2006
    ..To determine whether atypical antipsychotic polytherapy is a risk factor for drug treatment for extrapyramidal side-effects (anti-EPS drugs) and whether the risk is attributable to antipsychotic dose...
  4. ncbi request reprint Acute ethanol intoxication after consumption of hairspray
    Ryan M Carnahan
    Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Oklahoma, Tulsa, Oklahoma 74315 2512, USA
    Pharmacotherapy 25:1646-50. 2005
    ..The source and its components should be identified as soon as possible in order to assess other potential toxicities...
  5. ncbi request reprint Ziprasidone, a new atypical antipsychotic drug
    R M Carnahan
    Clinical and Administrative Pharmacy Division, College of Pharmacy, University of Iowa, Iowa City 52242-1112, USA
    Pharmacotherapy 21:717-30. 2001
    ..In contrast, ziprasidone has a low propensity for causing weight gain. For patients requiring an antipsychotic drug, ziprasidone represents a new treatment option with a limited adverse effect profile...
  6. ncbi request reprint Rivastigmine-induced dystonia
    Clay J Pavlis
    Sanford School of Medicine, University of South Dakota USD, Sioux Falls 57110, USA
    Am J Health Syst Pharm 64:2468-70. 2007
    ..A case of acute dystonia related to rivastigmine use is reported...
  7. ncbi request reprint Severe hyperlipidemia associated with olanzapine and quetiapine use
    Ryan M Carnahan
    Am J Psychiatry 164:1614-5. 2007
  8. ncbi request reprint Clozapine-induced leukopenia successfully treated with lithium
    Eric C Kutscher
    College of Pharmacy, South Dakota State University, Sioux Falls, SD 57110, USA
    Am J Health Syst Pharm 64:2027-31. 2007
    ..A case of clozapine-induced leukopenia successfully treated with lithium is reported...
  9. ncbi request reprint Quetiapine for acute mania in bipolar disorder
    Nancy C Brahm
    Department of Pharmacy Clinical and Administrative Sciences, University of Oklahoma College of Pharmacy UOCP, Tulsa, OK 74135 2512, USA
    Am J Health Syst Pharm 64:1045-53. 2007
    ..The efficacy and tolerability of quetiapine in the treatment of acute mania were reviewed...
  10. ncbi request reprint The concurrent use of anticholinergics and cholinesterase inhibitors: rare event or common practice?
    Ryan M Carnahan
    Clinical and Administrative Pharmacy, College of Pharmacy, University of Iowa, Iowa City, USA
    J Am Geriatr Soc 52:2082-7. 2004
    ..To measure the prevalence of anticholinergic use cross-sectionally in patients receiving cholinesterase inhibitors and to describe change in use of anticholinergics upon inception of cholinesterase inhibitor treatment...
  11. ncbi request reprint Methodological concerns in a trial of ziprasidone and olanzapine
    Ryan M Carnahan
    Am J Psychiatry 162:1391; author reply 1391-2. 2005
  12. ncbi request reprint A critical appraisal of the utility of the serum anticholinergic activity assay in research and clinical practice
    Ryan M Carnahan
    University of Iowa, College of Pharmacy, 415 S Pharmacy Building, Iowa City, Iowa 52242 1112, USA
    Psychopharmacol Bull 36:24-39. 2002
    ....
  13. ncbi request reprint Aripiprazole, a novel atypical antipsychotic drug
    Tami R Argo
    College of Pharmacy, University of Iowa, Iowa City, Iowa 52242 1112, USA
    Pharmacotherapy 24:212-28. 2004
    ..Patients receiving aripiprazole experienced EPS at a rate similar to that seen with placebo. Aripiprazole provides a new treatment option with limited adverse effects for patients in need of antipsychotic therapy...
  14. doi request reprint Hypomania with agitation associated with varenicline use in bipolar II disorder
    Anne E Morstad
    Ann Pharmacother 42:288-9. 2008
  15. ncbi request reprint The association of weight gain and olanzapine plasma concentrations
    Paul J Perry
    Department of Clinical and Administrative Pharmacy, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
    J Clin Psychopharmacol 25:250-4. 2005
    ..The association of weight gain with plasma concentrations during treatment with olanzapine may support the utilization of plasma drug concentration as a marker for antipsychotic-induced weight gain in the treatment of schizophrenia...